From COVID-19
Jump to navigation Jump to search


Abbott et al. Development of CRISPR as a Prophylactic Strategy to Combat Novel Coronavirus and Influenza, March 14, 2020, bioRxiv.

Ahn et al. Unique Loss of the PYHIN Gene Family in Bats Amongst Mammals: Implications for Inflammasome Sensing. Sci Rep 6, 21722 (2016).

Ai et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology, February 26, 2020.

Amanat et al. A serologic assay to detect SARS-CoV-2 seroconversion in humans. MedRxiv,

Alsoussi, W.B. et al. A potently neutralizing antibody protects mice against SARS-COV-2 infection. J. Immunol 205:915-922 (2020).

Ameri A, Rahnama N, Bozorgmehr R, et al. Low dose whole lung irradiation for COVID-19 pneumonia: short course results. Int J Rad Oncol Biol Phys (in press)

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder, Fifty Edition. Arlington, VA, 2013.

Amici et al. Indomethacin has a Potent Antiviral Activity Against SARS Coronavirus. Antivir Ther., 2006, 11(8): 1021-30.

Anand, P., Puranik, A., Aravaduman, M., et al. SARS-CoV-2 strategically mimics proteolytic activation of human ENaC. eLife, 2020.

Anderson et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. The New England Journal of Medicine, September 29, 2020.

Arunachalam, P.S. et al. Systems biological assessment of immunity to mild versus severe COVID-19 infections in humans. Science, 2020.

Auld et al. ICU and Ventilator Mortality Among Critically Ill Adults with Coronavirus Disease 2019. Critical Care Medicine, March 26, 2020.

Axfors et al. Mortality Outcomes with Hydroxychloroquine and Chloroquine in COVID-19: An International Collaborative Meta-Analysis of Randomized Trials. MedRxiv, September 18, 2020.

Balsari, S., Buckee, C., Khanna, T. Which Covid-19 data can you trust? Harvard Business Review May 8, 2020.

Bailey, C., Black, J.R.M., Swanton, C. Cancer Research: The lessons to learn from COVID-19. Cancer Discovery, September 2020.

Bancos et al. Ibuprofen and Other Widely Used Non-steroidal Anti-Inflammatory Drugs Inhibit Antibody Production in Human Cells. Cell Immunology, 2009, 258(1): 18-28.

Baranovich et al. T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 Viruses In Vitro. Journal of Virology, 87(7): 3741-3751, April 2013.

Baratchian, M., McManus, J., Berk, M., et al. No evidence than androgen regulation of pulmonary YMPRSS2 explains sex-discordant COVID-19 outcomes. bioRxiv (2020)

Barreca, A., Shimshack, J. Absolute Humidity, Temperature, and Influenza Mortality: 30 Years of County-Level Evidence from the United States. American Journal of Epidemiology, 176 Supplement 7: S114-22, October 2012.

Basu et al. Performance of the Rapid Nucleic Amplification by Abbott ID NOW COVID-19 in Nasopharyngeal Swabs Transported in Viral Media and Dry Nasal Swabs, in a New York City Academic Institution. BioRxiv, May 12, 2020.

Baum et al. Antibody Cocktail to SARS-CoV-2 Spike Protein Prevents Rapid Mutational Escape Seen with Individual Antibodies. Science, August 21, 2020.

Baum et al. REGN-CoV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus monkeys and hamsters. Science, 2020.

Beigel, J.H., Tomashek, K.M., Dodd, L.E., et al. Remdesevir for the treatment of Covid-19 – Preliminary report. NEJM DOI: 10.1056/NEJMoa200764.

Belyi et al. Electrostatic Origin of the Genome Packaging in Viruses. Proceedings of the National Academy of Sciences U.S.A., Nov. 14, 2006; 103(46):17174-8.

Bendavid et al. COVID-19 Antibody Seroprevalence in Santa Clara County, California. MedRxiv, April 17, 2020.

Berkley, S. COVID-19 needs a Manhattan Project, Science, 2020.

Besedovsky et al. Sleep and Immune Function. European Journal of Physiology, 2012, 463: 121-137.

Blanco-Melo et al. Imbalanced Host Cell Response to SARS-CoV-2 Drives Development of COVID-19. Cell, May 15, 2020.

Bonanno, G.A., Gupta, S. 2009. Resilience after disaster. In Neria Y, Galea S, Norris FH, eds. 2009. Mental Health and Disasters. New York: Cambridge Univ. Press, pp. 145–60.

Borba et al. Chloroquine Diphosphate in Two Different Dosages as Adjunctive Therapy of Hospitalized Patients with Severe Respiratory Syndrome in the Context of Coronavirus (SARS-CoV-2) Infection: Preliminary Safety Results of a Randomized, Double-Blinded, Phase IIb Clinical Trial (ChloroCid-19 Study), April 11, 2020. MedRxiv.

Borno HT, Small EJ. Does the COVID-19 outbreak identify a broader need for an urgent transformation of cancer clinical trials research? Contemporary Clinical Trials 92: (2020).

Borrell. New York Clinical Trial Quietly Tests Heartburn Remedy Against Coronavirus. Science, April 26, 2020. doi:10.1126/science.abc4739

Bouhaddou M et al., The global phosphorylation landscape of SARS-CoV-2 infection. Cell 182:1-28, 2020.

Bourouib, Lydia. Turbulent Gas Clouds and Respiratory Pathogen Emissions. JAMA Insights, March 26, 2020; 323(18):1837-1838.

Brainard J. New tools aim to tame pandemic paper tsunami. Science 368:924-925 (2020).

Brandt, A.M. and Botelho, A. Not a perfect storm – Covid-19 and the importance of language. New England J Med 382:1493-1495 (2020).

Breslin, N., Baptiste, C., Gyamfi-Banneman, C., et al. COVID-19 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals. Am J Obstet Gynecol MFM.2020.

Britton et al. A Mathematical Model Reveals the Influence of Population Heterogeneity on Herd Immunity to SARS-CoV-2. Science, August 14, 2020.

Broughton et al. CRISPR-Cas12-Based Detections of SARS-CoV-2. Nature Biotechnology, April 16 2020.

Buonanno et al. Far-UVC Light Efficiently and Safely Inactivates Airborne Human Coronaviruses. Virology pre-print, under review, April 27, 2020.

Caly et al. The FDA-Approved Drug Ivermectin Inhibits the Replication of SARS-CoV-2 in Vitro. Antiviral Research, April 3 2020.

Cameron et al. Preliminary Evidence that Higher Temperatures are Associated with Lower Incidence of COVID-19, for Cases Reported Globally up to 29th February 2020. March 2020.

Candelario, K.M. and Steindler, D.A., The role of extracellular vesicles in the progression of neurodegenerative disease and cancer. Trends Mol Med, 2014.

Candelario, K.M. et al., Exosome/Microvesicle content is altered in LRRK2 mutant iPS-derived neural cells. J. Comp Neurol, 2020.

Cannell et al. Epidemic Influenza and Vitamin D. Epidemiology & Infection, 2006, 134(6): 1129-1140.

Cao et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. New England Journal of Medicine, March 18, 2010.

Cao, L. et al. De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. Science 10.1126/science.abd9909 (2020).

Carlucci et al. Hydroxychloroquine and Azithromycin Plus Zinc vs. Hydroxychloroquine and Azithromycin Alone: Outcomes in Hospitalized COVID-19 Patients. MedRxiv, May 8, 2020.

Centers for Disease Control and Prevention. Interim considerations for infection prevention and control of coronavirus disease 2019 (COVID-19) in inpatient obstetric healthcare settings (2020)

Centers for Disease Control and Prevention. Interim guidance for use of pooling procedures in SARS-Cov-2 Diagnostic, screening, and surveillance testing. Updated 1 August, 2020 (accessed 16 October, 2020).

Chandrashekar et al. SARS-CoV-2 Infection Protects Against Rechallenge in Rhesus Macaques. Science, May 20, 2020.

Chang et al. The SARS Coronavirus Nucleocapsid Protein -- Forms and Functions. Antiviral Research, March 2014.

Chen et al. A Pilot Study of Hydroxychloroquine in Treatment of Patients with Common Coronavirus Disease-19 (COVID-19). Journal of Zhejiang University, March 2020.

Chen, W. et al. SARS-associated Coronavirus Transmitted from Human to Pig. Emerging Infectious Diseases, March 2005; 11(3):446-448.

Chen, Z. et al. Efficacy of Hydroxychloroquine in Patients with COVID-19: Results of a Randomized Clinical Trial. MedRxiv, April 10, 2020.

Chevalier et al. Massively parallel de novo protein design for targeted therapeutics. Nature 550:74-79 (2017).

Chin et al. Stability of SARS-CoV-2 in Different Environmental Conditions. The Lancet Microbe, April 2, 2020.

Chou, R., Pappas, M., Buckley, D., et al. Use of chest imaging in COVID-19 a rapid advice guide. World Health Organization. WHO-2019-nCoV-Clinical-Radiology_imaging-Web_Annex_A-2020.1-eng

Cohen, J. Russia’s Approval of a COVID-19 Vaccine is Less than Meets the Press Release. Science, August 11, 2020.

Complaint, State v. Stine, No. 20-2-09935-0 SEA (Wash. Super. Ct. June 12, 2020),

Consiglio et al. The immunology of multisystem inflammatory syndrome in children with COVID-19. Cell 183:1-14, 2020.

Corey, L., Mascola, J.R., Fauci, A.S. and F.S. Collins. A strategic approach to COVID-19 vaccine R&D. Science, 2020.

CoroNope, CoroNope: A Crowdsourced SARS-CoV-2 Vaccine (2020),

Cortillez-Ty et al. Severe Acute Respiratory Syndrome Nonstructural Protein 2 Interacts with a Host Protein Complex Involved in Mitochondrial Biogenesis and Intracellular Signalling. Journal of Virology, September 2009.

Coutard et al. The Spike Glycoprotein of the New Coronavirus 2019-nCoV Contains a Furin-Like Cleavage Site Absent in CoV of the Same Clade. Antiviral Research, April 2020, 176, 104742.

Dai M., Liu D., Liu M., et al. Patients with cancer appear to be more vulnerable to SARS-COV-2: A multi-center study during the COVID-19 outbreak. April, 2020

Dai W., Zhang B., Jiang X.-M., et al. Structure based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 368:1331-1335 (2020).

Daneshkhah et al. The Possible Role of Vitamin D in Suppressing Cytokine Storm and Associated Mortality in COVID-19 Patients. MedRxiv, April 30, 2020.

De Clercq et al. Therapeutic Options for the 2019 Novel Coronavirus (2019-nCoV), Nature Reviews Drug Discovery, February 10, 2020.

de Vries et al., Intranasal fusion inhibitory lipopeptide prevents direct SARS-CoV-2 transmission in ferrets. bioRxiv, 2020.

Deng, W et al., Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science, 369:818, August 14, 2020

Diao et al. Reduction and Functional Exhaustions of T Cells in Patients with Coronavirus Disease 2019. MedRxiv. February 20, 2020.

Dinnon et al. A mouse-adapted SARS-CoV-2 model for the evaluation of medical countermeasures. bioRxiv, 2020.

Dou et al. De novo design of a fluorescence-activating beta-barrel. Nature 561:485-491 (2018)

Duan et al. Effectiveness of Convalescent Plasma Therapy in Severe Covid-19 Patients. Proceedings of the National Academy of Sciences of the United States of America, April 6, 2020.

Dyal et al. COVID-19 Among Workers in Meat and Poultry Processing Plants Facilities - 19 States, April 2020. Morbidity and Mortality Weekly Report, May 8, 2020; 69(18): 557-561.

Ellinghaus et al. Genomewide Association Study of Severe COVID-19 with Respiratory Failure. The New England Journal of Medicine, June 17, 2020.

Endo et al. Estimating the Overdispersion in COVID-19 Transmission Using Outbreak Sizes Outside China. Wellcome Open Research, 2020; 5:67.

Escher et al. Severe COVID-19 Infection Associated with Endothelial Activation. Thrombosis Research, April 13, 2020.

Estep et al. for the Rapid Deployment Vaccine Collaborative (RaDVaC). SARS-CoV-2 (2019-nCoV).

Fang, L. et al. Are Patients with Hypertension and Diabetes Mellitus at Increased Risk for COVID-19 Infection? Lancet Respiratory Medicine, March 11, 2020.

Fang, Y. et al. Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR. Radiology, February 19, 2020.

Fehr, A.R., Perlman S. (2015) Coronaviruses: An Overview of Their Replication and Pathogenesis. In: Maier H., Bickerton E., Britton P. (eds) Coronaviruses. Methods in Molecular Biology, vol 1282. Humana Press, New York, NY.

Filippi, A.R., Russi, E., Magrini, S.M., Corvò, R. COVID-19 Outbreak in Northern Italy: First Practical Indications for Radiotherapy Departments, International Journal of Radiation Oncology (2020) j.ijrobp.2020.03.007

Fischer et al. Low-Cost Measurement of Facemask Efficacy for Filtering Expelled Droplets During Speech. Science Advances, August 7, 2020:

Fischhoff et al. Using the Psychological Science of Crisis Leadership and Communications to Navigate the Coronavirus: A Webinar for Public Officials (2020)

Fogarty A, et al. Pooled saliva samples for COVID-19 surveillance program. The Lancet (2020) .

Folegatti et al. Safety and Immunogenicity of the ChadOx1 nCoV-2019 Vaccine Against SARS-CoV-2: A Preliminary Report of a Phase I/II, Single-Blind, Randomised Controlled Trial. The Lancet, August 15, 2020, 396(10249): 467-478.

Foley et al. Growing Old, Yet Staying Young: The Role of Telomeres in Bats’ Exceptional Longevity. Science Advances, February 7, 2018, 4(2).

Forrey et al. Electrostatics of Capsid-Induced Viral RNA Organization. The Journal of Chemical Physics, September 14, 2009; 131(10): 105101.

Forster et al. Phylogenetic Network Analysis of SARS-CoV-2 Genomes. Proceedings of the National Academy of Sciences of the United States of America, April 8, 2020.

Freedberg et al. Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Study. MedRxiv, May 8, 2020.

Frontera J et al. A prospective study of neurologic disorders in hospitalized COVID-19 patients in New York. Neurology, 2020.

Furuta et al. T-705 (Favipiravir) and Related Compounds: Novel Broad-spectrum Inhibitors of RNA Viral Infections. Antiviral Research, 82(3): 95-102, June 2009.

Gautret, P., Lagier, J.-C., Parola, P. et al. Clinical and Microbiological Effect of a Combination of Hydroxychloroquine and Azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study. March 2020. International Journal of Antimicrobial Agents.

Galano et al. On the Free Radical Scavenging Activities of Melatonin’s Metabolites, AFMK and AFK. Journal of Pineal Research, April 2013, 54(3): 245-257.

Ghinai, I. et al., First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA, the Lancet, 395 10230 P1137-1144 April 4, 2020

Goldberg, P. Class of drugs used to treat CAR T-cell toxicity may reduce COVID-19 deaths. The Cancer Letter March 27, 2020

Goldman, E. and Galea, S. The Mental Health Consequences of Disasters. Annual Review of Public Health Vol. 35: 169-183, March, 2014.

Gordon et al. A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing. bioRxiv.

Graham et al. Evaluation of the Immunogenicity of Prime-Boost Vaccination with the Replication-Deficient Viral Vectored COVID-19 Vaccine Candidate ChadOx1 nCoV-2019. bioRxiv, June 20, 2020.

Grein et al. Compassionate Use of Remdesivir for Patients with Severe COVID-19. The New England Journal of Medicine, April 10, 2020.

Grifoni et al. A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2. Cell Host & Microbe, March 16, 2020.

Grifoni et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell, June 25, 2020. 181: 1489-1501.

Gu, H. et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine therapy. Science, 369: 1603-1607, 2020.

Guérin et al. Prone Positioning in Severe Acute Respiratory Distress Syndrome. New England Journal of Medicine, 2013; 368:2159-2168.

Guerrini et al. Self–experimentation, ethics, and regulation of vaccines. Science 369:1570-1572 (2020).

Guo et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clinical Infectious Diseases, March 21, 2020.

Hansen J, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369:1010, August 21, 2020.

Hao Yao, H., Chen, J., and Yi-Feng, X. Patients with mental health disorders in the COVID-19 epidemic. The Lancet. Volume 7, Issue 4, Pe21, April 01, 2020

Haschke et al. Pharmacokinetics and Pharmacodynamics of Recombinant Human Angiotensin-Converting Enzyme 2 in Healthy Human Subjects. Clinical Pharmacokinetics. September 2013; 52: 783-792.

Hellerstein, M. What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2? Vaccine: X 6 (2020) 100076

Herold et al. Levels of IL-6 Predicts Respiratory Failure in Hospitalized Symptomatic COVID-19 Patients. MedRxiv:

Hess, C.B., Buchwald, Z.S., Stokes, W. et al. Low-dose whole-lung radiation for COVID-19 pneumonia: Planned Day-7 interim analysis of an ongoing clinical trial. MedRxiv doi:

Hoffmann et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell 181:2020

Holshue et al. First Case of 2019 Novel Coronavirus in the United States. The New England Journal of Medicine 2020, 382: 929-936.

Horby et al. Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary Results from a Multi-Centre, Randomized, Clinical Trial. MedRxiv, July 15, 2020.

Horton R. Offline: Science and the breakdown of trust. The Lancet 396:945 (2020).

Huang, A. et al. A Systematic Review of Antibody Mediated Immunity to Coronaviruses: Antibody Kinetics, Correlates of Protection, and Association of Antibody Responses with Severity of Disease. MedRxiv, April 17, 2020.

Huang, C. et al. Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. The Lancet February 15, 2020, 395(10223): p. 497-506.

Imai et al. Angiotensin-converting Enzyme 2 Protects from Severe Acute Lung Failure. Nature 2005, 436(7047): 112-116.

Isho et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Science Immunology, October 8, 2020.

Iyer et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 in COVID-19 patients. Science Immun., 2020.

Jackson et al. An mRNA Vaccine Against SARS-CoV-2–Preliminary Report. The New England Journal of Medicine, July 14, 2020.

Jaimes, J.A., Millet, J.K., and Whittaker, G.R. Proteolytic cleavage of the SARS-CoV-2 spike protein and the role of the novel S1/S2 site. iSCIENCE (2020), doi:

Jin, Z. et al. Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature (2019)

Johnson, K. Brutal plan to restrict palliative radiotherapy during pandemic. MedScape Oncology (2020).

Joyner et al. Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients. MedRxiv, May 14, 2020.

Joyner et al. Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience. MedRxiv, August 12, 2020.

Kaneko, N. et al. Loss of BcL-6-expressing T follicular helper cells and germinal centers in COVID-19, Cell, 2020.

Kang et al. Crystal Structure of SARS-CoV-2 Nucleocapsid Protein RNA Binding Domain Reveals Potential Unique Drug Targeting Sites. Acta Pharmaceutica Sinica B, July 2020.

Kariko et al. Incorporation of Pseudouridine into mRNA Yields Superior Nonimmunogenic Vector with Increased Translational Capacity and Biological Stability. Mol. Ther. 16, 1833- 1840 (2008).

Keyaerts, E. et al. Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle. Antiviral Research, 75:179-187, 2007.

Khan et al. A Pilot Clinical Trial of Recombinant Human Angiotensin-Converting Enzyme 2 in Acute Respiratory Distress Syndrome. Critical Care. September 2017; 21(1): 234.

Kim et al. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development. eBioMedicine. (2020).

Kirsch, D.G., Diehn, M., Cucinotta, F.A., Weichselbaum, R. Lack of supporting data make the risk of a clinical trial of radiation therapy as a treatment for COVID-19 pneumonia unacceptable. Radiotherapy and Oncology 147:217-220, 2020.

Korainik IJ and KL Tyler, COVID-19: A global threat to the nervous system. In press, 2020.

Konno et al. SARS-CoV-2 ORF3b is a Potent Interferon Antagonist Whose Activity is Further Increased by a Naturally Occurring Elongation Variant. BioRxiv, Mar 12, 2020.

Kopecky-Bromberg et al. Severe Acute Respiratory Syndrome Coronavirus Open Reading Frame (Orf) 3b, ORF6, and Nucleocapsid Proteins Function as Interferon Antagonists. Journal of Virology, January 2007, 81(2): 548-557.

Korber et al. Spike Mutation Pipeline Reveals the Emergence of a More Transmissible Form of SARS-CoV-2. BioRxiv April 30, 2020.

Kuba et al. A Crucial Role of Angiotensin Converting Enzyme 2 (ACE2) in SARS Coronavirus-Induced Lung Injury. Nature Medicine 2005, 11(8): 875-879.

Kumar, N et al. Integrative network biology framework elucidates molecular mechanisms of SARS-CoV-2 pathogenesis. iScience, 2020.

Lai A. G., Pasea L., Banerjee A., et al. Estimating excess mortality in people with cancer and multimorbidity in the COVID-19 emergency. ResearchGate DOI: 10.13140/RG.2.2.34254.82242 (2020)

Lan, J., Ge, J., Yo, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature published online 30 March 2020.

Lara, P., Burgos, J., Macias, D. Low dose lung radiotherapy for COVID-19 pneumonia. The rationale for a cost-effective anti-inflammatory treatment. Clinical and Translational Radiation Oncology 23:27-29 (2020).

Latham, J., Wilson, A. A Proposed Origin for SARS-CoV-2 and the COVID-19 Pandemic. Independent Science News, July 15, 2020.

Laurer et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) from Publicly Reported Confirmed Cases; Estimation and Application. Annals of Internal Medicine, March 10, 2020; 172 (9): 577-582.

Lavezzo et al. Suppression of a SARS-CoV-2 Outbreak in the Italian Municipality of Vo’. Nature, April 2020.

Leask, H. Huge Global Push for RCTs in COVID-19: From Random to Randomized., April 4, 2020.

Le Bert, N. et al., SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature, 2020.

Leclerc et al. What Settings have been Tied to SARS-CoV-2 Transmission Clusters? Wellcome Open Research, 2020, 5:83.

Leng et al. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcomes of Patients with COVID-19 Pneumonia. Aging and Disease 2020, 11(2): 216-228.

Leonhardt, D. The Singapore warning. New York Times 16 April, 2020.

Li, R. et al. Substantial Undocumented Infection Facilitates the Rapid Dissemination of Novel Coronavirus (SARS-CoV-2). Science, March 2020, doi: 10.1126/science.abb3221.

Li, X.C. et al. The Vasoprotective Axes of the Renin-Angiotensin System: Physiological Relevance and Therapeutic Implications in Cardiovascular, Hypertensive, and Kidney Diseases. Pharmacological Research, November 2017, 125(Part A): 21-38.

Li, W., et al. High potency of a bivalent human VH domain in SARS-CoV-2 animal models. Cell, 2020.

Li, Y.C.,Bai, W.Z.,Hashikawa, T. The neuroinvasive potential of SARS-CoV2 may be at least partially responsible for the respiratory failure of COVID-19 patients, J Med Virol. 2020 Feb 27. doi: 10.1002/jmv.25728. [Epub ahead of print]

Li, Y., Wang, M. et al. Acute Cerebrovascular Disease Following COVID-19: A Single Center, Retrospective, Observational Study. The Lancet pre-print, March 13, 2020.

Liang, W., Guan, W., Chen, R. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncology 21:335-337 (2020).

Lighter et al. Obesity in Patients with Younger than 60 Years is a Risk Factor for COVID-19 Hospital Admission. Clinical Infectious Diseases, April 9, 2020.

Lin, L., Fu, G., Chen, S., et al. CT manifestations of coronavirus disease (COVID-19) pneumonia and influenza virus pneumonia: a comparative study. Am J Radiol 216:1-9 (2021).

Lipsitch et al. Absolute Humidity and Pandemic Versus Epidemic Influenza. American Journal of Epidemiology, January 2011, 173(2): 127-135.

Liu, J., et al. Large SARS-CoV-2 Outbreak Caused by Asymptomatic Traveler, China. Emerging Infectious Diseases, June 30, 2020.

Liu, L., et al. Potent Neutralizing Antibodies Directed to Multiple Epitopes on SARS-CoV-2 Spike. Nature, July 22, 2020.

Liu, Y., Gayle, A., Wilder-Smith, A., and Rocklöv, J., (2020). The reproductive number of COVID-19 is higher compared to SARS coronavirus. Journal of Travel Medicine.

Liu, Y. et al. Viral Dynamics in Mild and Severe Cases of COVID-19. The Lancet Infectious Disease, March 19, 2020.

Logunov, D. et al. Safety and Immunogenicity of an rAd26 and rAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine in Two Formulations: Two Open, Non-Randomised Phase I/II Studies from Russia. The Lancet, September 4, 2020.

Lokugamage et al. SARS-CoV-2 is Sensitive to Type I Interferon Pretreatment. BioRxiv. (2020)

London A.J. and Kimmelman J. Against pandemic research exceptionalism. Science 358:476-477 (2020).

Long et al. Antibody Responses to SARS-CoV-2 in Patients with COVID-19. Nature Medicine, April 29, 2020.

Long et al. Clinical and Immunological Assessment of Asymptomatic SARS-CoV-2 Infections. Nature Medicine, June 18, 2020.

Lovren et al. Angiotensin Converting Enzyme-2 Confers Endothelial Protection and Attenuates Atherosclerosis. American Journal of Physiology, October 1, 2008.

Luo, J., Rizvi, H., Egger, J.V., et al. Impact of PD-1 blockage on severity of COVID-19 in patients with lung cancer. Cancer Discovery 10:1-8 (2020).

MacLean et al. Response to “On the origin and continuing evolution of SARS-CoV-2”.

Magagnoli, J., Narendran, S., Pereira, F. et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv preprint doi:

Maguen, S., Neria, Y., Conoscenti, L.M., Litz, B.T. Depression and prolonged grief in the wake of disasters. In Neria Y, Galea S, Norris FH, eds. 2009. Mental Health and Disasters. New York: Cambridge Univ. Press, pp. 116–30.

Mancia et al. Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19. New England Journal of Medicine, May 1, 2020. DOI: 10.1056/NEJMoa2006923.

Mann E R et al. Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19. Science Immunol., 2020.

Martineau et al. Vitamin D Supplementation to Prevent Acute Respiratory Tract Infections: Systematic Review and Meta-Analysis of Individual Participant Data. BMJ, 2017; 356:i6583.

Mateus et al. Selective and Cross-Reactive SARS-CoV-2 T Cell Epitopes in Unexposed Humans. Science, August 4, 2020.

Mathew D et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science, 369:1209, 2020.

Maziarz, R.T. et al., Single and multiple dose MultiStem (multipotent adult progenitor cell) therapy prophylaxis of acute graft-versus-host disease in myeloablative allogeneic hematopoietic cell transplantation: a phase 1 trial. Biol Blood Marrow Transplant. 2015 Apr;21(4):720-8. doi: 10.1016/j.bbmt.2014.12.025. Epub 2014 Dec 30.

McCarty et al. Nutraceuticals have Potential for Boosting the Type 1 Interferon Response to RNA Viruses Including Influenza and Coronavirus. Progress in Cardiovascular Diseases, February 2020.

McCray et al. Lethal Infection of K18-hACE2 Mice Infected with Severe Acute Respiratory Syndrome Coronavirus. Journal of Virology, 2007; 81: 813-821.

Mehra et al. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. New England Journal of Medicine, May 1, 2020. DOI: 10.1056/NEJMoa2007621.

Mehra et al. Hydroxychloroquine or Chloroquine with or without a Macrolide for Treatment of COVID-19: A Multinational Registry Analysis. The Lancet, May 22, 2020.

Mehta V., Goel S., Kabarriti R., et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. DOI:10.1158/2159-8290.CD-20-0516 (2020)

Melin et al. Comparative ACE2 Variation and Primate COVID-19 Risk. MedRxiv, April 19, 2020.

Mesin, L. et al. Restricted clonality and limited germinal center reentry characterize memory B cell reactivation by boosting. Cell, 180, 2020.

Mikkonen L., Pihlajamaa P., Sahu B., et al. Androgen receptor and androgen-dependent gene expression in lung. Mol Cell Endocrinol 317:14-24 (2020).

Molina et al. No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection. Médecine et Maladies Infectieuses, March 30, 2020.

Monteil et al. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell, April 24, 2020.

Moore J.B. and June C.H., Cytokine release syndrome in severe COVID-19. Science 368:473-474 (2020)

Montopoli M, Zumerle S, Vettor R, et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532). Annals of Oncology (2020), doi:

Moseman EA et al., T cell engagement of cross-presenting microglia protects the brain from a nasal viral infection. Science Immunology, 2020.

Mosites et al. Assessment of SARS-CoV-2 Infection Prevalence in Homeless Shelters - Four U.S. Cities, March 27 - April 15, 2020. Morbidity and Mortality Weekly Report, May 1, 2020; 69(17): 521-522.

Mou, H., Raj, V. S., van Kuppeveld, F. J., Rottier, P. J., Haagmans, B. L., and Bosch, B. J. The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. Journal of virology, 87(16), 9379–9383 (2013).

Mulligan, et al. Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. MedRxiv, July 1, 2020.

Munster et al. ChAdOx1 nCoV-19 Vaccination Prevents SARS-CoV-2 Pneumonia in Rhesus Macaques. BioRxiv, May 13, 2020.

Neal, MM. Fake cures and real law: Analyzing the legal implications of DIY COVID vaccines. The Wake Forest Law Review, 22 September 2020.

Neria, Y., Galea, S., Norris, F.H., eds. Mental Health and Disasters. New York: Cambridge Univ. Press

Neria, Y., Nandi, A., Galea, S. 2008. Post-traumatic stress disorder following disasters: a systematic review. Psychol. Med. 38:467–80.

Netea et al. BCG Vaccination Protects Against Viral Infection in Humans Through the Induction of Cytokines Associated with Trained Immunity. Cell Host and Microbe, January 2018, 23(1): P89-100.

Nishiura et al. Closed Environments Facilitate Secondary Transmission of Coronavirus Disease 2019. MedRxiv, April 16, 2020.

Nguyen, et al. Virus Against Virus: A Potential Treatment for 2019-nCoV (SARS-CoV-2) and other RNA Viruses. Cell Research: 30:189-190, 2020.

Norris Wind LH. The experience of disaster: trauma, loss, adversities, and community effects. In Neria, Y., Galea, S., Norris, F.H., eds. Mental Health and Disasters. New York: Cambridge University Press.

O’Dwyer, P. Letter to ECOG-ACRIN Investigators (March 25, 2020). See also for more recent updates.

Oesterreich et al. Successful Treatment of Advanced Ebola Virus Infection with T-705 (Favipiravir) in a Small Animal Model, Antiviral Research May 2014, 105: 17-25.

Offord C. The Surgisphere scandal: What went wrong? The Scientist, October 1, 2020.

Okba et al. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients. Emerging Infectious Diseases, July 2020 early release, 26(9).

Olena, A. SARS-CoV-2 spike protein shares sequences with a human protein. The Scientist. June 1, 2020.

Olival, K. et al. Host and Viral Traits Predict Zoonotic Spillover from Humans. Nature June 21, 2017, 546: 646-650.

Ou et al. Characterization of Spike Glycoprotein of SARS-CoV-2 on Virus Entry and its Immune Cross-Reactivity with SARS-CoV. Nature Communications March 27, 2020, 11(1): 1620. doi:10.1038/s41467-020-15562-9

Oxley et al. Large-Vessel Stroke as a Presenting Feature of COVID-19 in Young. The New England Journal of Medicine, April 28, 2020.

Pan et al. Viral Load of SARS-CoV-2 in Clinical Samples. Lancet Infectious Diseases, February 24, 2020; 20(4), 411–412.

Pan H. for the WHO Solidarity Trial Consortium. Repurposed antiviral drugs for COVID-19 - interim WHO SOLIDARITY trial results.

Patterson et al. Evidence of Exposure to SARS-CoV-2 in Cats and Dogs from Households in Italy. BioRxiv, July 23, 2020.

Pearman et al. Age differences in risk and resilience factors in COVID-19 related stress. The Journals of Gerontology, 2020.

Pierce et al. Immune responses of SARS-CoV-2 infection in hospitalized pediatric and adult patients. Science Translational Medicine, September 21, 2020.

Pino, L., Perez, C., Cardona, A., and Triana, I. Cancer center recommendations to mitigate COVID-19 impact in patients with cancer: low-resource settings version. JCO Global Oncology published at on April 13, 2020. DOI:

Poh et al. Two Linear Epitopes on the SARS-CoV-2 Spike Protein that Elicit Neutralizing Antibodies in COVID-19 Patients. Nature Communications, June 1, 2020. 11, 2806.

Premkumar L et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Science Immunol., 2020.

Puntmann et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered from Coronavirus Disease 2019 (COVID-19). JAMA Cardiology, July 27, 2020.

Qian et al. Indoor Transmission of SARS-CoV-2. MedRxiv, April 16, 2020.

Qin, Bao et al. Reinfection Could not Occur in SARS-CoV-2 Infected Rhesus Macaques. BioRxiv,

Qing et al. QTY Code Designed Thermostable and Water-Soluble Chimeric Chemokine Receptors with Tunable Ligand Affinity. Proceedings of the National Academy of Science of the United States of America, December 17, 2019, 116(51): 25668-25676,

Raptis, C.A., Hammer, M.M., Short, R.G. et al. Chest CT and Coronavirus Disease (COVID-19): A critical review of the literature to date. AJR 215:1-4 (2020).

Regaldo. Some scientists are taking a DIY coronavirus vaccine, and nobody knows if it’s legal or if it works. MIT Technology Review, July 29, 2020.

Reynolds et al. Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19. New England Journal of Medicine, May 1, 2020. DOI: 10.1056/NEJMoa2008975.

Rhodes J., Chan C., Paxson C., Rouse E., Waters M., and Fussell, E. The Impact of Hurricane Katrina on the Mental and Physical Health of Low-Income Parents in New Orleans. Am J Orthopsychiatry. 2010 Apr; 80(2): 237–247.

Richardson et al. Barcitinib as a Potential Treatment for 2019-nCoV Acute Respiratory Disease. The Lancet, 395(10223): E30-31.

Rijkers, G. et al. Differences in antibody kinetics and functionality between severe and mild SARS-CoV-2 infections. J Infect Dis, July 29, 2020.

Riva, L. et al., Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature, 2020.

Robilotti, E.V., Babady, N.E., Mead, P.A., et al. Determinants of COVID-19 disease severity in patients with cancer. Nature Medicine 26: 1218-1223 (2020).

Rödel, F., Arenas, M., Ott, O.J., et al. Low-dose radiation therapy for COVID-19 pneumopathy: what is the evidence? Strahlentherapie Onkology (2020)

Rogers TF et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science, 369:956, 2020.

Roschewski, M., Lionakis, M.S., Sharman, J.P., et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci. Immunol. 10.1126/sciimmunol.abd0110 (2020)

Ruan et al. Clinical Predictors of Mortality Due to COVID-19 Based on an Analysis of 150 Patients from Wuhan, China. Intensive Care Medicine, April 6, 2020.

Rubin, G.D., Ryerson, C.J., Haramati, L.B., et al. The role of chest imaging in patient management during the COVID-19 pandemic – A Multinational Consensus Statement from the Fleischner Society. Radiology 296:172-180 (2020).

Sahin et al. Concurrent Human Antibody and TH1 Type T-Cell Responses Elicited by a COVID-19 Vaccine. July 20, 2020.

Salazar et al. Treatment of COVID-19 Patients with Convalescent Plasma in Houston, Texas. MedRxiv, May 13, 2020.

Salmon, D.A. and Dudley, M.Z. It is time to get serious about vaccine confidence. The Lancet 396-870-871 (2020)

Salomaa, S., Cardis, E., Simon, D.. Bouffler, S.D., et al. Low dose radiation therapy for COVID-19 pneumonia: Is there any supportive evidence?, International Journal of Radiation Biology, 2020

Sánchez-Guijo et al. Adipose-Derived Mesenchymal Stromal Cells for the Treatment of Patients with Severe SARS-CoV-2 Pneumonia Requiring Mechanical Ventilation. A Proof of Concept Study. EClinical Medicine, July 4, 2020.

Sanjuan, R., Nebot, M., Chirico, N., Mansky, L., and Belshaw, R., Viral Mutation Rates, J. Virology, Vol. 84, No. 19 , pgs. 9733-9748 (2010)

Santarpia et al. Aerosol and Surface Contamination of SARS-CoV-2 Observed in Quarantine and Isolation Care. Scientific Reports 10, 12732, July 29, 2020.

Santillana et al. Role of Absolute Humidity on Transmission Rates of the COVID-19 Outbreak. MedRxiv. February 2020.

Servick, K. and Enserink, M. A mysterious company’s coronavirus papers in top medical journals may be unravelling. doi:10.1126/science.abd1337

Sen et al. Electroceutical Fabric Lowers Zeta Potential and Eradicates Coronavirus Infectivity Upon Contact. ChemRxiv, May 15, 2020.

Seow et al. Longitudinal Evaluation and Decline of Antibody Responses in SARS-CoV-2 Infection. MedRxiv, July 11, 2020.

Seto et al. The Effects of Temperature and Relative Humidity on the Viability of the SARS Coronavirus. Advances in Virology 2011.

Sharifi, N. and Ryan, C.J. Androgen hazards with COVID-19. Endocrine-Related Cancer 27: E1-E3 (2020).

Sheahan et al. Broad-spectrum Antiviral GS-5734 Inhibits Both Epidemic and Zoonotic Coronaviruses. Science Translational Medicine, June 28, 2017, 9(396). 10.1126/scitranslmed.aal3653

Sheahan et al. An orally bioavailable broad-spectrum antiviral inhibits 1 SARS-CoV-2 and multiple

2 endemic, epidemic and bat coronavirus. bioRxiv:

Shen et al. Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma. Journal of the American Medical Association, March 27, 2020.

Shi, J. et al. Susceptibility of Ferrets, Cats, Dogs, and Different Domestic Animals to SARS-Coronavirus-2. BioRxiv, March 31, 2020.

Shi, S. et al. Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19 in Wuhan, China. JAMA Cardiology, March 25, 2020.

Shirato et al. Wild-Type Human Coronaviruses Prefer Cell-Surface TMPRSS2 to Endosomal Cathepsins for Cell Entry. Virology, April 2018, 517: 9-15.

Shrock, E. et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science, 2020.

Shuman, A.G., Pentz, R.D. Cancer research ethics and COVID-19. The Oncologist 25:458-459 (2020)

Sidaway P. COVID-19 and cancer: what we know so far. Nature Reviews Clinical Oncology. Published online 7 April, 2020

Silverman, E., Feuerstein, A., Herper, M. New data on Gilead’s remdesevir, released by accident,show no benefit for coronavirus patients. Company still sees reason for hope. Accessed at 23 April, 2020.

Sit et al. Infection of Dogs with SARS-CoV-2. Nature, May 14, 2020.

Smith et al. Immunogenicity of a DNA Vaccine Candidate for COVID-19. Nature Communications 11, 2601 (2020).

Society for Maternal Fetal Medicine. Coronavirus (COVID-19) and pregnancy: what maternal fetal medicine subspecialists need to know. 2020.

Somers, E.C., Eschenauer, G.A., Troost, J.P. et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. medRx doi:

Song et al. Neuroinvasive Potential of SARS-CoV-2 Revealed in Human Brain Organoid Model. bioRxiv, June 26, 2020.

Sontag, S. Illness as metaphor and AIDS and its metaphors. New York: Picador 2001.

Srinivasan et al. Melatonin in Bacterial and Viral Infections with Focus on Sepsis: A Review. Recent Patents on Endocrine, Metabolic, & Immune Drug Discovery, 2012, 6(1): 30-39.

Stebbing et al. COVID-19: Combining antiviral and anti-inflammatory treatments, 2020. The Lancet, Comment (February 27, 2020)

Steindler, D.A. and Reynolds, B.A. Perspective: Neuroregenerative Nutrition, Adv. Nutr. 2017 8, 546-57; doi:

Sterne JAC for the WHO Rapid Evidence Appraisal for COVID-19Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19 - A meta-analysis. JAMA doi:10.1001/jama.2020.17023

Substance Abuse and Mental Health Services Administration: Communicating in a Crisis: Risk Communication Guidelines for Public Officials. SAMHSA Publication No. PEP19-01-01-005. Rockville, MD, Substance Abuse and Mental Health Services Administration, 2019.

Summerfield, J. A. Clinical potential of mannose-binding lectin-replacement therapy. Biochem Soc Transac 31:770, 2003.

Tang, N. et al. Abnormal Coagulation Parameters are Associated with Poor Prognosis in Patients with Novel Coronavirus Pneumonia. Journal of Thrombosis and Haemostasis, February 19, 2020.

Tang, X. et al. On the Origin and Continuing Evolution of SARS-CoV-2, National Science Review

te Velthuis et al. Zn2+ Inhibits Coronavirus and Arteririvirus RNA Dependent RNA Polymerase Activity In Vitro and Zinc Ionophores Block the Replication of These Viruses in Cell Culture. Plos Pathogens 6(11), November 2010. Biochem Soc Trans 31: 770, 2003.

The American College of Obstetrics and Gynecologists. Practice Advisory: Novel Coronavirus 2019 (COVID-19).

Tian et al. Potent Binding of 2019 Novel Coronavirus Spike Protein by a SARS Coronavirus-Specific Human Monoclonal Antibody. Emerging Microbes and Infections, February 17, 2020, 9(1): 382-385.

Thoms et al. Structural Basis for the Translational Shutdown and Immune Evasion by the Nsp1 Protein of SARS-CoV. BioRxiv, May 18, 2020.

Toubiana et al. Outbreak of Kawasaki Disease in Children During the COVID-19 Pandemic: A Prospective Observational Study in Paris, France. MedRxiv, May 14, 2020.

Tsoi et al. The SARS-Coronavirus Membrane Protein Induces Apoptosis via Interfering with PDK1-PKB/Akt Signalling. The Biochemical Journal, December 15, 2014. https://doi/org/10.1042/BJ20131461

Ueda, M., Martins, R., Hendrie, P.C. et al. Managing cancer care during the COVID-19 pandemic; Agility and collaboration toward a common goal. JNCCN 18:1-4 (2020).

Umapathi et al. Large Artery Ischaemic Stroke in Severe Acute Respiratory Syndrome (SARS). Journal of Neurology, 2004, 251(10): 1227-1231. doi: 10.1007/s00415-004-0519-8

U.S. Food and Drug Administration. Pooled sample testing and screening testing for COVID-19. Updated 24 August, 2020 (accessed 16 October, 2020).

Valdimarsson et al. Human plasma-derived mannose-binding lectin: A phase 1 safety and pharmacokinetic study, Scandanavian J Immunology 59, 97-102, 2004.

Valitutto et al. Detection of Novel Coronaviruses in Bats in Myanmar. PLOS ONE, April 9, 2020.

Van Doremalen et al. Aerosol and Surface Stability of HCoV-19 (SARS-CoV-2) Compared to SARS-CoV-1. MedRxiv.

Verdia-Baguena et al. Coronavirus E Protein Forms Ion Channels with Functionally and Structurally Involved Membrane Lipids. Virology, October 25, 2012; 432(2): 485-494.

Verdoni et al. An Outbreak of Severe Kawasaki-like Disease at the Italian Epicentre of the SARS-CoV-2 Epidemic; An Observational Cohort Study. The Lancet, May 13, 2020.

Vincent et al. Chloroquine is a Potent Inhibitor of SARS Coronavirus Infection and Spread. Virology Journal, 2005.

Vogels et al. SalivaDirect: Simple and Sensitive Molecular Diagnostic Test for SARS-CoV-2 Surveillance. MedRxiv, August 4, 2020.

de Vrieze. Can a Century-Old TB Vaccine Steel the Immune System Against the New Coronavirus? Science (2020)

Walsh et al. RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study. MedRxiv, August 28, 2020.

Wang, C. et al. A Human Monoclonal Antibody Blocking SARS-CoV-2 Infection. Nature Communications 11(2251), May 4, 2020.

Wang, H. et al. SARS Coronavirus Entry into Host Cells Through a Novel Clathrin- and Caveolae-Independent Endocytic Pathway. Nature Cell Research, Feb 2008(2): 290-301.

Wang, K. et al. SARS-CoV-2 Invades Host Cells via a Novel Route: CD-147 Spike Protein. BioRxiv, March 14, 2020.

Wang, X. et al. SARS-CoV-2 Infects T Lymphocytes Through its Spike Protein-Mediated Membrane Fusion. Cellular and Molecular Immunology, April 7, 2020.

Wang, Y. et al. Remdesivir in Adults with Severe COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial. The Lancet, April 29, 2020.

Waterhouse, D., Harvey, R., Hurley, P., et al. Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-term Opportunities for Transformation: Findings from an American Society of Clinical Oncology Survey DOI: 10.1200/ OP.20.00275

Welch, D. et al. Far-UVC light: A new tool to control the spread of airborne-mediated microbial diseases, Nature Scientific Reports 8, 2752 (2018).

Wichmann et al. Autopsy Findings and Venous Thromboembolism in Patients with COVID-19. Annals of Internal Medicine, May 6, 2020.

Williams, C. Low dose chest radiation for COVID-19 patients. 27 April, 2020.

Woelfel et al. Clinical Presentation and Virological Assessment of Hospitalized Cases of Coronavirus Disease 2019 in Travel-Related Cluster. MedRxiv, March 8, 2020.

Wolff, G et al. A molecular pore spans the double membrane of the coronavirus replication machinery. Science, September 11, 2020.

Wrapp, D., Wang. N. et al. Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. Science 367(6483): 1260-1273. doi: 10.1126/science.abb2507.

Wrapp, D., McLellan, J. et al. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. Cell, 181, May 28, 2020.

Wright, J.L., Alcorn, S., McNutt, T. et al. An integrated program in a pandemic: Johns Hopkins radiation oncology department. Advances in Radiation Oncology.

Wu, F. et al. Neutralizing Antibody Responses to SARS-CoV-2 in a COVID-19 Recovered Patient Cohort and their Implications. MedRxiv, April 6, 2020.

Wu, F.Q. et al. SARS-CoV-2 Titers in Wastewater are Higher than Expected from Clinically Confirmed Cases. MedRxiv, April 7, 2020.

Wu S., Zheng D., Liu Y. et al. Radiotherapy during a major outbreak of COVID-19 in Wuhan. Advances in Radiation Oncology (2020).

Xia, X. et al. Extreme Genomic Deficiency in SARS-CoV-2 and Evasion of Host Antiviral Defense. Molecular Biology and Evolution, April 14, 2020.

Xia, Y., Jin, R., Xhao, J. et al. Risk of COVID-19 for Patients with Cancer. Lancet Oncology, March 3, 2020

Xiao, F., et al. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology, March 3, 2020; 158(6): 1831-1833.e3.

Xiao, T., et al. Isolation and Characterization of 2019-CoV-like Coronavirus from Malayan Pangolins. BioRxiv.

Xu, Xiaoling et al. Effective Treatment of Severe COVID-19 Patients with Tocilizumab. ChinaXiv 202003.00026 (2020)

Yao et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases, March 9, 2020.

Yao, H. et al. Patient-derived mutation impact pathogenicity of SARS-CoV-2, MedRxiv,

Yeramilli, D., Xu, A.J., Gillespie, E.F. et al. Palliative radiotherapy for oncologic emergencies in the setting of COVID-19: Approaches to balancing risks and benefits. Adv Radiation Oncol 2020 MS # D-20-00082R1.

Yoshimoto, FK. The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2 or SARS-nCoV), the Cause of COVID-19. The Protein Journal, May 23, 2020.

You, B., Ravaud, A., Canivet, A. et al. The official French guidelines to protect patients with cancer against SARS-CoV-2 infection. Lancet Oncology. March 25, 2020.

Yu, J., Ouyang, W., Chua, M., Xie, C. SARS-CoV-2 Transmission in Patients with Cancer at Tertiary Care Hospital in Wuhan, China. JAMA Oncol [about:blank] 25 March, 2020.

Yuan, M. et al. A Highly Conserved Cryptic Epitope in the Receptor-Binding Domains of SARS-CoV-2 and SARS-CoV, Science 10.1126/science.abb7269 (2020).

Zhang, G. et al. First In-Class Peptide Binder to the SARS-CoV-2 Spike Protein. BioRxiv. (2020).

Zhang, G. et al. Comparative Analysis of Bat Genomes Provides Insight into the Evolution of Flight and Immunity. Science, January 25, 2013. 339(6118): 456-460.

Zhang, L., Zhu, F., Xie, L. et al. Clinical characteristics of COVID-19 infected cancer patients: a retrospective case study in three Ann Oncol Published online 26 March, 2020.

Zhang, S., et al. QTY Code Enables Design of Detergent-Free Chemokine Receptors that Retain Ligand-Binding Activities. Proceedings of the National Academy of Sciences of the United States of America, August 28, 2018, 115(37): E8652-E8659.

Zhang, T., et al. Pangolin Homology Associated with 2019-nCoV. BioRxiv (2020).

Zhang, Y., et al, Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 Years: Report of the Randomized, Double-Blind, and Placebo-Controlled Phase II Clinical Trial. MedRxiv, August 10, 2020.

Zhavoronkov et al. Potential COVID-2019 3C-Like Protease Inhibitors Designed Using Generative Deep Learning Approaches. ChemRxiv. (2020)

Zheng, M., Gao, Y., Wang, G. et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cellular and Molecular Immunology (2020).

Zheng, M., Song, L. Novel Antibody Epitopes Dominate the Antigenicity of Spike Glycoprotein in SARS-CoV-2 Compared to SARS-CoV. Cellular and Molecular Immunology, March 4, 2020, 17: 536-538.

Zhou, F. et al. Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study. Lancet, 2020, 395: 1054-1062. S0140-6736(20)30566-3

Zhou, P. et al. Contraction of the type I IFN locus and unusual constitutive expression of IFN-α in bats. Proceedings of the National Academy of Sciences, 2016, 113:2696–2701. doi: 10.1073/pnas.1518240113.

Zhou, P. et al. A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin. Nature, 579:270-273 (February 3, 2020).

Zhou, Y., Hou, Y., Shen, J. et al. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov 6, 14 (2020).

Zhu F., et al. Immunogenicity and Safety of a Recombinant Adenovirus Type-5-Vectored COVID-19 Vaccine in Healthy Adults Aged 18 Years or Older: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. The Lancet, 396(10249): 479-488 (July 20, 2020).

Zhu, F. et al. Safety, Tolerability, and Immunogenicity of a Recombinant Adenovirus Type-5 Vectored COVID-19 Vaccine: A Dose-Escalation, Open-Label, Non-Randomised, First-in-Human-Trial. The Lancet, 395(10240): 1845-1854 (May 22, 2020).

Zhu, L. et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-Existing Type 2 Diabetes. Cell Metabolism, May 1, 2020.

Zhu, N. et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. The New England Journal of Medicine, 382: 727-733. (2020).

Ziegler et al. SARS-CoV-2 Receptor ACE2 is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and is Enriched in Specific Cell Subsets Across Tissues. Cell, March 17, 2020.

Zou et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020

Zoufaly, A. et al. Human recombinant soluble ACE2 in severe COVID-19. The Lancet Respiratory Medicine, 2020.

Zunin, Myers. Substance Abuse and Mental Health Service Administration (SAMHSA)